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A 54 year old woman had unintentional weight loss of 12-19 kg with nausea, abdominal 
discomfort, and constipation over 2-3 months. She presented acutely with profuse vomiting for 
three days. She was taking venlafaxine 150 mg/day for bipolar disorder, she smoked (40 pack 
years), consumed little alcohol, and had no family history of disease. On examination, she was 
dehydrated, her blood pressure was 106/74 mm Hg, pulse 122 beats/min and regular, and her 
temperature was 37.2°C. She had a smooth symmetrical goitre with no retrosternal extension or 
lymphadenopathy, and mild abdominal tenderness. Systems examination was normal. She 
underwent blood tests, the results of which were normal for renal function, alkaline 
phosphatase, total protein, globulin, and protein electrophoresis. Abnormal blood test results 
are shown in table 1. 
Chest radiography and computed tomography scans of the abdomen and pelvis were 
normal. 
Table 1 Abnormal blood test results 
Test Result Reference range 
Potassium 3.0 mmol/L 3.5-5.3 
Adjusted calcium 3.02 mmol/L 2.20–2.60 
Phosphate 1.06 mmol/L 0.8-1.5 
Parathyroid hormone (PTH) <0.4 pmol/L 1.3-9.3 
Alanine transaminase (ALT) 256 IU/L <50 
Free thyroxine (FT4) 63.3 pmol/L 9.2-21 
Free triiodothyronine (FT3) >46.1 pmol/L 2.6-5.7 
Thyroid-stimulating hormone 
(TSH) 
<0.02 mU/L 0.3-4.4 
TSH receptor antibody (TRAb) >40 IU/L <0.9 
Vitamin D 37 nmol/L >50 
Angiotensin-converting enzyme 
(ACE) 
64 U/L 8-52 
Questions 
1. What are the possible causes of this patient’s hypercalcaemia? 
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2. What is the most likely diagnosis? 
3. How would you treat this patient? 
1. What are the possible causes of this patient’s hypercalcaemia? 
Print answer 
This patient has non-PTH mediated hypercalcaemia (low PTH, high adjusted calcium).  
 Causes include: 
- Malignancy (eg lung, breast, kidney, skin, multiple myeloma, lymphoproliferative 
disorders)  
- Granulomatous disorders (eg sarcoidosis, tuberculosis) 
- Drugs - e.g. vitamin D and vitamin A toxicity, thiazide diuretics, calcium supplements 
causing milk alkali syndrome, vitamin A  
- Endocrine disorders  (eg, thyrotoxicosis/hyperthyroidism, phaeochromocytoma, 
hypoadrenalism, VIPoma)  
- Immobilisation  
Online answer 
This patient has non-PTH mediated hypercalcaemia (low PTH and high adjusted calcium 
levels).  
In PTH mediated hypercalcaemia, PTH levels are inappropriately raised, ie, detectable, and 
within or above the reference range. In non-PTH mediated hypercalcaemia, PTH is below the 
reference range or undetectable. The causes of both are summarised in table 2. 
Table 2 A summary of the causes of PTH mediated and non-PTH mediated 
hypercalcaemia 
PTH mediated hypercalcaemia Non-PTH mediated hypercalcaemia 
Primary hyperparathyroidism 
• Adenoma 
• Hyperplasia 
• carcinoma 
 
Malignancy 
• multiple myeloma 
• lymphoproliferative disorders 
• lung 
• breast 
• kidney 
• skin Familial benign hypocalciuric hypercalcaemia 
 
Tertiary hyperparathyroidism Granulomatous disease 
• Sarcoidosis 
• tuberculosis 
Drugs  
• lithium 
 
Endocrine disorders 
• Thyrotoxicosis/hyperthyroidism/Graves 
disease 
• Pheochromocytoma 
• Hypoadrenalism 
• VIPoma 
Ectopic PTH production resulting from 
malignancy (rare) 
Drugs  
• Vitamin D toxicity 
• Thiazide diuretics 
• Calcium supplements (causing milk-alkali 
syndrome)  
• Vitamin A toxicity 
• calcium and calcitriol or vitamin D 
analogues for chronic renal failure 
 Immobilisation 
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Adapted from Minisola et al.1 
 
Primary malignancies (eg, lung, breast, kidney, skin) cause hypercalcaemia by producing 
PTH related peptide (PTHrP), and by causing bone destruction. PTHrP produces similar effects 
to PTH, ie, increases gut and renal tubular calcium absorption, and activates osteoclast bone 
resorption—all causing an increase in serum calcium. Secondary malignancies cause bone 
destruction by producing osteoclast activating cytokines and PTHrP locally.2 Rarely, 
malignancies (eg, lymphoproliferative disorders) may cause hypercalcaemia by increasing 
vitamin D3 (by activating the 1-α-hydroxylase enzyme), or causing ectopic PTH production 
(ovarian, small cell, and squamous lung cancers). 
Hypercalcaemia of multiple myeloma is also mediated through cytokines and occurs in 30% 
of cases. Most patients with normal renal function in multiple myeloma will adapt to the 
increased calcium load and not develop hypercalcaemia. 
In granulomatous disorders and some lymphomas, activated 1-α-hydroxylase causes 
vitamin D3 overproduction which increases renal and gastrointestinal absorption of calcium.  
Hypercalcaemia occurs in approximately 20% of patients with thyrotoxicosis, and is 
uncommon, asymptomatic, and mild in Graves’ disease.4 The hypercalcaemia of Graves’ 
disease is caused by FT3 mediated osteoclast activation, increasing bone turnover and transfer 
of calcium from bone to serum.3 Rising calcium levels will suppress PTH through a negative 
feedback mechanism and PTH will be low or undetectable. Although calcium absorption from 
the intestines is reduced and renal calcium excretion is increased in thyrotoxicosis,5 FT3 
stimulated osteoclast activation results in a net increase in calcium levels, and hypercalcaemia. 
2. What is the most likely diagnosis? 
Print answer 
Hyperthyroidism due to Graves’ disease, causing non-PTH mediated hypercalcaemia. 
Classical features of Graves’ disease include tachycardia, weight loss, a smooth 
symmetrical goitre, and high TRAb levels. The patient also presented with relatively 
uncommon features of Graves’ disease: hypercalcaemia with normal serum phosphate, and 
biochemical evidence of hepatitis. The hypercalcaemia of Graves’ disease is caused by FT3 
mediated osteoclast activation, increasing bone turnover and transfer of calcium from bone to 
serum. 
Online answer 
Hyperthyroidism due to Graves’ disease causing non-PTH mediated hypercalcaemia. 
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Classic clinical features of Graves’ disease include tachycardia, weight loss, a smooth 
symmetrical goitre, and high TRAb levels. This patient also presented with two relatively 
uncommon features of Graves’ disease: hypercalcaemia with normal serum phosphate 
(resulting from absent PTH, and phosphate conservation by thyroid hormones) and biochemical 
evidence of hepatitis. In 15%-76% of people with Graves’ disease, liver enzymes are 
abnormal.7 This results from thyroid hormone or drug induced liver damage (eg, by 
thionamides), concomitant autoimmune liver disease; and heart failure, singly or in 
combination.  
TRAb (detectable in 90%-95% of patients with Graves’ disease) stimulates the TSH 
receptor, increasing serum thyroid hormone levels. 
If renal function is not impaired, normal serum phosphate and hypercalcaemia are good 
indicators of non-PTH mediated hypercalcaemia. Phosphate is low in PTH-mediated 
hypercalcaemia because PTH is phosphaturic (eg, in primary hyperparathyroidism).  
In thyrotoxicosis, high FT3 levels activate mitochondrial induced liver apoptosis,8 and the 
liver vasculature fails to keep up with increased cellular oxygen demands. A mild increase of 
the transaminases therefore occurs.  
3. How would you treat this patient? 
Print answer 
Immediate management involves rapid rehydration with intravenous normal saline infusion 
(to increase glomerular filtration and calcium excretion) and intravenous bisphosphonates (to 
inhibit osteoclast activation.) 
Next, treat the hyperthyroidism with oral thionamides after warning the patient about side 
effects, especially neutropenia and liver toxicity. If thionamides are unsuitable or there is 
relapse, consider radioiodine or thyroidectomy with lifetime levothyroxine. 
Online answer 
Treatment involves: 
1. Rehydration—Vomiting and renal salt/water wasting (hypercalcaemia induced 
nephrogenic diabetes insipidus) can substantially deplete volume in hypercalcaemia. 
Rehydration increases glomerular filtration and excretion of calcium. Infusion rates are 
guided by age, severity of hypercalcaemia, and the presence of heart or renal 
compromise. Recommended regimens using 0.9% normal saline are (a) 200-300 
ml/hour initially, adjusted to maintain a 100-150 ml/hour urine output; (b) 3-4 L daily; 
(c) 1-2 L bolus followed by 200-250 ml hourly. 
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2. Bisphosphonates—Pamidronate and zoledronic acid infusions inhibit osteoclast 
activation. Zoledronic acid is superior to pamidronate in efficacy and duration of 
response. Both 4 mg and 8 mg (given as 15 minute infusions) are superior to 90 mg of 
pamidronate (2 hour infusion).11  Zoledronic acid reduces calcium slightly more quickly 
and normalises calcium in 80%-100% in less than three days. A second dose, if 
necessary, can be given after eight days. Calcitonin, loop diuretics, and corticosteroids 
have a limited role. Denosumab is a relatively new osteoclast inhibiting human 
monoclonal antibody against RANK-L; its clinical utility is uncertain.1 
3. Thionamides—Treating Graves’ disease is important for controlling symptoms, 
hypercalcaemia, and liver injury. Thionamides (CBZ or MMI) are recommended as first 
line treatment. CBZ is started 40 mg/day (given once or twice/day). Graves’ disease will 
be controlled in about 4-6 weeks—the time taken to deplete intrathyroidal iodine stores 
and thyroid hormones. Dose titration is preferred (dose reduction every 4-6 weeks to the 
lowest effective dose of 5-10 mg/day, titrating dose against thyroid hormone response). 
This regimen is used for 12 months minimum (without benefit beyond 18 months). 
Some recommend a “block and replace” regimen—CBZ 40 mg/day, adding 
levothyroxine 100-125 µg/day when biochemically euthyroid and the combination 
usually continued for 6-9 months, with subsequent switch during the remaining period 
to low dose CBZ only. There is no advantage to either regimen in terms of recurrence.12 
Drugs for hyperthyroidism, thyrotoxicosis, and Graves disease (eg thionamides–
carbimazole, methimazole, propylthiouracil) can cause liver dysfunction and hepatitis-
like features.9 10 
4. If after stopping thionamides Graves’ disease relapses, definitive treatment with 
radioiodine or thyroidectomy is usually indicated, followed by lifelong replacement 
therapy with levothyroxine.12 
Learning points: 
• In non-PTH mediated hypercalcaemia, PTH is below the reference range or 
undetectable. In PTH mediated hypercalcaemia, PTH levels are inappropriately 
raised, ie, detectable, and within or above the reference range. 
• In Graves’ disease, hypercalcaemia with normal serum phosphate results from 
absent PTH and phosphate conservation by thyroid hormones. 
Patient outcome 
The patient responded well to rehydration with 0.9% saline, 60 mg pamidronate and 
potassium chloride infusions, and CBZ 40 mg/day (table 3). Thereafter, liver enzymes and 
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calcium remained normal persistently. She had a total thyroidectomy because her 
hyperthyroidism was not controlled, despite 18 months of high dose CBZ (she declined 
radioiodine). She remains euthyroid on lifelong levothyroxine (75 µg/day). 
Table 3 Patient outcome on treatment 
Investigation At 
admission 
Day 6 Reference 
range 
Adjusted calcium (mmol/L) 3.02 2.50 2.20-2.60 
Alanine transaminase (IU/L) 256 49 <50 
FT4 (pmol/L) 63.3 27.4 9.0–19.1 
FT3 (pmol/L) >46.1 13 2.6-5.7 
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